A Phase II, Randomized, Double-Blind, Multicenter, Parallel Group Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug RO5024048 in Combination With Boceprevir and Pegasys®/Copegus® in Patients With Chronic Hepatitis C Genotype 1 Virus Infection Who Were Prior Null Responders to Treatment With Pegylated Interferon/Ribavirin
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Boceprevir (Primary) ; Mericitabine (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms DYNAMO-1
- Sponsors Genentech; Roche
- 13 Apr 2014 Results presented at the 49th Annual Meeting of the European Association for the Study of the Liver.
- 24 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrial.gov.
- 09 Dec 2013 Planned end date changed from 1 Feb 2014 to 1 Jan 2014 as reported by ClinicalTrials.gov.